Summary
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
- The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
Betagenon AB
Can-Fite BioPharma Ltd.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Corcept Therapeutics Incorporated
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 10
Therapeutics Development 11
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 11
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis 12
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies 13
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes 15
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies 20
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes 22
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 23
Arisaph Pharmaceuticals, Inc. 23
AstraZeneca Plc 24
Betagenon AB 25
Can-Fite BioPharma Ltd. 26
Cerenis Therapeutics Holding SA 27
Conatus Pharmaceuticals Inc. 28
Corcept Therapeutics Incorporated 29
Daewoong Pharmaceutical Co., Ltd. 30
Dimerix Bioscience Pty Ltd 31
Dr. Falk Pharma GmbH 32
DURECT Corporation 33
Eternygen GmbH 34
Galmed Pharmaceuticals Ltd. 35
Huons Co., Ltd. 36
Kyorin Pharmaceutical Co., Ltd. 37
Matinas BioPharma Holdings, Inc. 38
Novartis AG 39
NovaTarg Therapeutics, Inc 40
Osel, Inc. 41
Sancilio & Company, Inc. 42
TaiwanJ Pharmaceuticals Co., Ltd. 43
TCM Biotech International Corp 44
Tobira Therapeutics, Inc. 45
Zafgen Inc. 46
Zydus Cadila Healthcare Limited 47
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
(leucine + PDE5 Inhibitor) - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
AC-261066 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Aramchol - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ARI-3037MO - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
AZD-4076 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
C-10 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
CBM-588 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
cenicriviroc mesylate - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
CER-209 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
CF-102 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
CORT-118335 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
dapagliflozin propanediol - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
DMX-300 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
DUR-928 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
DWP-10292 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
emricasan - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
FLB-12 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
HU-002 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
KDT-501 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
MAT-8800 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
MN-002 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
naltrexone hydrochloride - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
norursodeoxycholic acid - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
O-304 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
oltipraz - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
pradigastat sodium - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
RT-200 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
RT-210 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
saroglitazar - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
SC-410 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
TCM-606F - Drug Profile 127
Product Description 127
Mechanism Of Action 127
R&D Progress 127
ZGN-839 - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 129
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 131
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 132
Featured News & Press Releases 132
Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions 132
Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China 132
Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial 133
May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting 133
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 133
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 134
Jan 11, 2016: Can-Fite Announces Update on CF102 135
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 135
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment 136
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 137
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease 138
May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study 138
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 139
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 140
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 141
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 143
Disclaimer 144
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016 11
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 23
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2016 24
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2016 25
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd., H2 2016 26
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 27
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 28
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Incorporated, H2 2016 29
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 30
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 31
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016 32
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H2 2016 33
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2016 34
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016 35
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H2 2016 36
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 37
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 38
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2016 39
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 40
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Osel, Inc., H2 2016 41
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company, Inc., H2 2016 42
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 43
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2016 44
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H2 2016 45
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2016 46
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 47
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Stage and Target, H2 2016 51
Number of Products by Stage and Mechanism of Action, H2 2016 54
Number of Products by Stage and Route of Administration, H2 2016 57
Number of Products by Stage and Molecule Type, H2 2016 59
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2016 129
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects (Contd..1), H2 2016 130
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2016 131
List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016 11
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Top 10 Targets, H2 2016 50
Number of Products by Stage and Top 10 Targets, H2 2016 50
Number of Products by Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Routes of Administration, H2 2016 56
Number of Products by Stage and Routes of Administration, H2 2016 56
Number of Products by Molecule Types, H2 2016 58
Number of Products by Stage and Molecule Types, H2 2016 58
